Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Transferrin-functionalized liposomes for docetaxel delivery to prostate cancer cells

Full text
Author(s):
Fernandes, Mariza Aires [1] ; Eloy, Josimar O. [2] ; Luiz, Marcela Tavares [3] ; Ramos Junior, Sergio Luiz [4] ; Borges, Julio Cesar [4] ; de la Fuente, Laura Rodriguez [5] ; Luis, Clara Ortega-de San [6] ; Marchetti, Juliana Maldonado [3] ; Santos-Martinez, Maria J. [5, 6, 7] ; Chorilli, Marlus [1]
Total Authors: 10
Affiliation:
[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, Araraquara, SP - Brazil
[2] Fed Univ Ceara UFC, Coll Pharm Dent & Nursing, Fortaleza, Ceara - Brazil
[3] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Ribeirao Preto, SP - Brazil
[4] Univ Sao Paulo, Sao Carlos Inst Chem, Sao Carlos, SP - Brazil
[5] Univ Dublin, Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Trinity Biomed Sci Inst, Dublin 2 - Ireland
[6] Univ Dublin, Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci Inst, Dublin 2 - Ireland
[7] Univ Dublin, Trinity Coll Dublin, Sch Med, Trinity Biomed Sci Inst, Dublin 2 - Ireland
Total Affiliations: 7
Document type: Journal article
Source: COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS; v. 611, FEB 20 2021.
Web of Science Citations: 0
Abstract

Prostate cancer (PC) is the second type of cancer, causing the greatest number of deaths among the male population in the world. An attractive approach to treat PC involves the superficial modification of liposomes with specific ligands to overexpressed receptors on the surfaces of tumor cells, such as transferrin receptors (TFR's). To our knowledge, this is the first time that transferrin-functionalized liposomes for delivery of DTX to prostate cancer cells were investigated. In this study, we developed and characterized docetaxel- loaded liposomes functionalized with transferrin (LIP-DTX-TF) and evaluated their effect on PC cell lines. The results showed that the systems had a nanometric size and the presence of DTX contributed to the reduction of the vesicle size and liposomes were stable. The encapsulation efficiency of DTX was approximately 69 and 37 % for liposomes with and without functionalization, respectively. The functionalization efficiency using TF was 31 %. The functionalization process did not affect the integrity of TF. DTX encapsulated in the liposomes showed slow and sustained release for LIP-DTX and LIP-DTX-TF (51.70 % and 31.97 %, respectively). The in vitro cytotoxicity assay in PC-3 and PNT2 cell lines suggest that LIP-DTX-TF was more toxic to PC-3 than the commercial formulation. Confocal microscopy proved that functionalized liposomes were successfully internalized in PC-3 cells. Furthermore, the interaction of these systems with the TFR's overexpressed on the cell surface was further corroborated using Quartz Crystal Microbalance with Dissipation technology (QCM-D). Therefore, although additional studies in three-dimensional cell models and in vivo xenograft studies are warranted, it can be concluded that the systems developed here are promising candidates for the delivery of docetaxel to prostate cancer cells. (AU)

FAPESP's process: 17/25190-8 - Evaluation of the potential of transferrin-functionalized liposomes for docetaxel delivery in the treatment of prostate cancer
Grantee:Mariza Aires Fernandes
Support Opportunities: Scholarships in Brazil - Master
FAPESP's process: 14/50928-2 - INCT 2014: Pharmaceutical Nanotechnology: a transdisciplinary approach
Grantee:Maria Vitória Lopes Badra Bentley
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 18/26422-2 - Evaluation of the potential of transferrin-functionalized liposomes for docetaxel delivery for the treatment of prostate cancer
Grantee:Mariza Aires Fernandes
Support Opportunities: Scholarships abroad - Research Internship - Master's degree